H2AX a promising biomarker for lung cancer: A review

Cancer Investigation

Volumn 31, Issue 9, 2013, Pages 582-599

  Matthaios, D ^a   Hountis, P ^b   Karakitsos, P ^c   Bouros, D ^a   Kakolyris, S ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ATHENS NAVAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Carcinogenesis; DNA damage response; H2AX; Lung cancer; PARP inhibitors

Indexed keywords

4B ACRYLAMIDOPODOPHYLLOTOXIN DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEFITINIB; HISTONE H2AX; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ROSCOVITINE; TOPOTECAN; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DNA DAMAGE; DRUG MECHANISM; GENOTOXICITY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMOKING;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION TOLERANCE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887222527     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.849721     Document Type: Article

References (160)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
3. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-183.
4. Rosell R, Felip E, Garcia-Campelo R, Balana C. The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 2004;46:135.
5. Redon C, Pilch DR, Rogakou E, Sedelnikova OA, Newrock, K, Bonner WM. Histone H2A variants h2ax and h2az. Curr Opin Genet Dev 2002;12: 162-169.
6. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNARepair (Amst. ) 2004;3:959-967.
7. Helt CE, ClibyWA, Keng PC, Bambara RA, O'Reilly MA. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem 2005;280:1186-1192.
8. Dupŕe A, Boyer-Chatenet L, Gautier J. Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex. Nat Struct Mol Biol 2006;13:451-457.
9. Sun Y, Jiang X, Chen S, Fernandes N, Price BD. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci USA 2005;102:13182-13187.
10. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATRdependent manner in response to replicational stress. J Biol Chem. 2001;276:47759-47762.
11. Mukherjee B, Kessinger C, Kobayashi J, Chen BP, Chen DJ, Chatterjee A, Burma S. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst) 2006;5:575-590.
12. Wang H, WangM, Wang H, B̈ockerW, Iliakis G. ComplexH2AX phosphorylation patterns by multiple kinases including ATM and DNA-PK in human cells exposed to ionizing radiation and treated with kinase inhibitors. J Cell Physiol 2005;202:492-502.
13. Ayoub N, Jeyasekharan AD, Bernal JA, Venkitaraman AR. HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature 2008;453:682-686.
14. Durocher D, Henckel J, Fersht AR, Jackson SP. The FHA domain is a modular phosphopeptide recognition motif. Mol Cell 1999;4:387-394.
15. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003;302:636-639.
16. Williams RS, Lee MS, Hau DD, Glover JN. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 2004;11:519-525.
17. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 2005;123:1213-1226.
18. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. 2005;434:605-611.
19. Chapman JR, Jackson SP. Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep 2008;9:795-801.
20. Kobayashi J, Antoccia A, Tauchi H, Matsuura S, Komatsu K. NBS1 and its functional role in the DNA damage response. DNA Repair (Amst) 2004;3:855-861.
21. Douglas P, Zhong J, Ye R, Moorhead GB, Xu X, Lees-Miller SP. Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates gamma-H2AX. Mol Cell Biol 2010;30:1368-1381.
22. Wu L, Luo K, Lou Z, Chen J. MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc Natl Acad Sci USA 2008;105:11200-11205.
23. HuenMS, Grant R,Manke I, Minn K, Yu X, Yaffe MB, Chen J. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007;131:901-914.
24. Stucki M, Jackson SP. gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair (Amst) 2006;5:534-543.
25. Wood JL, Singh N, Mer G, Chen J. MCPH1 functions in an H2AX-dependent but MDC1-independent pathway in response to DNA damage. J Biol Chem 2007;282:35416-35423.
26. Wright WE, Shay JW. Telomere-binding factors and general DNA repair. Nat Genet 2005;37:116-118.
27. Hao LY, Strong MA, Greider CW. Phosphorylation of H2AX at short telomeres in T cells and fibroblasts. J Biol Chem 2004;279:45148-45154.
28. KimJA, KruhlakM,Dotiwala F,Nussenzweig A,Haber JE. Heterochromatin is refractory to gamma-H2AXmodification in yeast and mammals. J Cell Biol 2007;178:209-218.
29. Lantuejoul S, Raynaud C, Salameire D, Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C, Brambilla E. Telomere maintenance and DNA damage responses during lung carcinogenesis. Clin Cancer Res 2010;16:2979-2988.
30. Raynaud CM, Mercier O, Commo F, Dartevelle P, Gomez-Roca C, de Montpreville V, Sabatier L, Soria JC. Telomere length, telomeric proteins andDNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. Lung Cancer 2009;65:144-149.
31. Ikura T, Ogryzko VV, Grigoriev M, Groisman, R, Wang J, Horikoshi M, Scully R, Qin J, Nakatani Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000;102:463-473.
32. Murr R, Loizou JI, Yang YG,Cuenin C, Li H,Wang ZQ,Herceg Z. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks Nat Cell Biol 2006;8:91-99.
33. Ikura T, Tashiro S, Kakino A, et al. DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics. Mol Cell Biol 2007;20:7028-7040.
34. Conaway RC, Conaway JW. The INO80 chromatin remodeling complex in transcription: replication and repair. Trends Biochem Sci 2009;34:71-77.
35. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, L̈obrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 2004;64:2390-2396.
36. Yin B, Savic V, Juntilla MM, Bredemeyer AL, Yang-Iott KS, Helmink BA, Koretzky GA, Sleckman BP, Bassing CH. Histone H2AX stabilizes broken DNA strands to suppress chromosome breaks and translocations during V(D)J recombination. J Exp Med 2009;206:2625-2639.
37. Yuan J, Chen J. MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. J Biol Chem 2010;285:1097-1104.
38. Xie A, Puget N, Shim I, Odate S, Jarzyna I, Bassing CH, Alt FW. Scully R Control of sister chromatid recombination by histone H2AX. Mol Cell 2004;16:1017-1025.
39. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000;14:397-402.
40. Xiao Y, Weaver DT. Conditional gene targeted deletion by Cre recombinase demonstrates the requirement for the doublestrand break repair Mre11 protein in murine embryonic stem cells. Nucleic Acids Res 1997;25:2985-2991.
41. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997;11:1226-1241.
42. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-810.
43. Chen PL, Liu F, Cai S, et al. Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency. Mol Cell Biol 2005;25:3535-3542.
44. Tsuzuki T, Fujii Y, Sakumi K, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 1996;93:6236-6240.
45. Elson A, Wang Y, Daugherty CJ, Morton CC, Zhou F, Campos-Torres J, Leder P. Pleiotropic defects in ataxiatelangiectasia protein-deficient mice. Proc Natl Acad Sci USA 1996;93:13084-13089.
46. StewartGS,Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of themammalian DNA damage checkpoint. Nature 2003;421:961-966.
47. Ebi H, Sato T, Sugito N, et al. Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009;28:3371-3379.
48. Huang QM, Tomida S,Masuda Y, et al. Regulation of DNA polymerase POLD4 influences genomic instability in lung cancer. 2010;70:8407-8416.
49. Matthew EM, Yen TJ, Dicker DT, Dorsey JF, Yang W, Navaraj A, El-DeiryWS. Replication stress: defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 2007;6:2571-2578.
50. OstlingO, JohansonKJ. Microelectrophoretic study of radiationinduced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 1984;123:291-298.
51. McArt DG, McKerr G, Howard CV, Saetzler K, Wasson GR. Modelling the comet assay. Biochem Soc Trans 2009;37:914-917.
52. Huang X, Halicka HD, Traganos F, Tanaka T, Kurose A, Darzynkiewicz Z. Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis. Cell Prolif 2005;38:223-243.
53. Darzynkiewicz Z,Huang X,Okafuji M. Detection ofDNA strand breaks by flow and laser scanning cytometry in studies of apoptosis and cell proliferation (DNA replication). MethodsMol Biol 2006;314:81-93.
54. L̈obrich M, Ikpeme S, Kiefer J. Measurement of DNA doublestrand breaks in mammalian cells by pulsed-field gel electrophoresis: a new approach using rarely cutting restriction enzymes. Radiat Res 1994;138:186-192.
55. Ismail IH, Wadhra TI, Hammarsten O. An optimized method for detecting gamma-H2AX in blood cells reveals a significant interindividual variation in the gamma-H2AX response among humans. Nucleic Acids Res 2007;35(5):e36.
56. Sak A, Grehl S, Erichsen P, et al. gamma-H2AX foci formation in peripheral blood lymphocytes of tumor patients after local radiotherapy to different sites of the body: dependence on the dosedistribution, irradiated site and time from start of treatment. Int J Radiat Biol 2007;83:639-652.
57. Avondoglio D, Scott T, Kil WJ, Sproull M, Tofilon PJ, Camphausen K. High throughput evaluation of gamma-H2AX. Radiat Oncol 2009;24;4:31.
58. Garty G, Chen Y, Turner, HC, et al. The RABiT: a rapid automated biodosimetry tool for radiological triage. II. Technological developments. Int J Radiat Biol 2011;87:776-790.
59. Wang LH, Pfister TD, Parchment RE, et al. Monitoring druginduced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010;16:1073-1084.
60. Qian W, Zhukov T, Song D, TockmanMS. Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer. Anal Quant Cytol Histol 2007;29:103-111.
61. Liedert B, Pluim D, Schellens J,Thomale J. Adduct-specificmonoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 2006;34(6):e47.
62. Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatininduced peripheral neuropathy. J Neurosci 2007;27:9451-9457.
63. PablaN,Huang S,MiQS, Daniel R, DongZ. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatininduced apoptosis. J Biol Chem 2007;283:6572-6583.
64. Oliver TG, Mercer KL, Sayles LC, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010;24:837-852.
65. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-1295.
66. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320.
67. Rabik CA, Fishel ML, Holleran JL, et al. Enhancement of cisplatin [cis-diamminedichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulumstress. J Pharmacol Exp Ther 2008;327:442-452.
68. Arora S, Kothandapani A, TillisonK, Kalman-MalteseV, Patrick SM. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) 2010;9:745-753.
69. Jeon JH, KimSK, Ki HJ, Chang J, Ahn CM, Chang YS. Insulinlike growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer. Cancer Lett 2008;272:232-241.
70. Iwasa T, Okamoto I, Takezawa K, et al. Marked anti-tumour activity of the combination of YM155: a novel survivin suppressant and platinum-based drugs. Br J Cancer 2010;103:36-42.
71. Lovejoy KS, Serova M, Bieche I, et al. Spectrum of cellular responses to pyriplatin: a monofunctional cationic antineoplastic platinum(II) compound in human cancer cells. Mol Cancer Ther 2011;10:1709-1719.
72. Jayachandran G, Ueda K, Wang B, Roth JA, Ji L. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS One 2010;5(8):e11994.
73. Wang HM, Cheng KC, Lin CJ, et al. Obtusilactone A and (?)-sesamin induce apoptosis in human lung cancer cells by inhibiting mitochondrial Lon protease and activating DNA damage checkpoints. Cancer Sci 2010;101:2612-2620.
74. Park JH, Kim EJ, Jang HY, et al. Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogenactivated protein kinases. Oncol Rep 2008;20:379-384.
75. Yang CS, Lu G, Ju J, Li GX. Inhibition of inflammation and carcinogenesis in the lung and colon by tocopherols. Ann N Y Acad Sci 2010;1203:29-34.
76. Lu G, Xiao H, Li GX, et al. A gamma-tocopherol-rich mixture of tocopherols inhibits chemically induced lung tumorigenesis in A/J mice and xenograft tumor growth. Carcinogenesis 2010;31:687-694.
77. Li GX, Chen YK, Hou Z, et al. Pro-oxidative activities and dose-response relationship of (?)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis 2010;31:902-910.
78. Rusin M, Zajkowicz A, Butkiewicz D. Resveratrol induces senescence-like growth inhibition ofU-2 OS cells associatedwith the instability of telomeric DNA and upregulation of BRCA1. Mech Ageing Dev 2009;130:528-537.
79. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913.
80. Bartkova J, Horejś? Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870.
81. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 2006;25:4381-4388.
82. Cirombella R, Montrone G, Stoppacciaro, A et al. Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. Cancer Lett 2010;291:230-236.
83. Nuciforo PG, Luise C, Capra M, Pelosi G, d'Adda di Fagagna F. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 2007;28:2082-2088.
84. BlancoD,Vicent S, FragaMF, et al. Molecular analysis of amultistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 2007;9:840-852.
85. Zhao H, Tanaka T, Mitlitski V, Heeter J, Balazs EA, Darzynkiewicz Z. Protective effect of hyaluronate on oxidative DNA damage in WI-38 and A549 cells. Int J Oncol 2008;32:1159-1167.
86. Albino AP, Huang X, Jorgensen E, Yang J, Gietl D, Traganos F, Darzynkiewicz Z. Induction of H2AX phosphorylation in pulmonary cells by tobacco smoke: a new assay for carcinogens. Cell Cycle 2004;3:1062-1068.
87. Gallmeier E, Winter JM, Cunningham SC, Kahn SR, Kern SE. Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX. Carcinogenesis 2005;26:1811-1820.
88. Ibuki Y, Toyooka T, Shirahata J, Ohura T, Goto R. Water soluble fraction of solar-simulated light-exposed crude oil generates phosphorylation of histoneH2AX in human skin cells under UVA exposure. Environ Mol Mutagen 2007;48:430-439.
89. Luo Q, Yang J, Zeng QL, Zhu XM, Qian YL, Huang HF. 50-Hertz electromagnetic fields induce gammaH2AX foci formation in mouse preimplantation embryos in vitro. Biol Reprod 2006;75:673-680.
90. DesaiN,DavisE,O'Neill P,DuranteM,CucinottaFA,WuH. Immunofluorescence detection of clustered gamma-H2AX foci induced by HZE-particle radiation. Radiat Res 2005;164:518-522.
91. Toyooka T, Ibuki Y. Cigarette side stream smoke induces phosphorylated histone H2AX. Mutat Res 2009;676:34-40.
92. Jorgensen ED, Zhao H, Traganos F, Albino AP, Darzynkiewicz Z. DNA damage response induced by exposure of human lung adenocarcinoma cells to smoke from tobacco-and nicotine-free cigarettes. Cell Cycle 2010;9:2170-2176.
93. Zhao H, Albino AP, Jorgensen E, Traganos F, Darzynkiewicz Z. DNA damage response induced by tobacco smoke in normal human bronchial epithelial andA549 pulmonary adenocarcinoma cells assessed by laser scanning cytometry. Cytometry A 2009;275:840-847.
94. Msiska Z, Pacurari M, Mishra A, Leonard SS, Castranova V, Vallyathan V. DNA double-strand breaks by asbestos, silica, and titanium dioxide: possible biomarker of carcinogenic potential? Am J Respir Cell Mol Biol 2010;43:210-219.
95. Albino AP, Huang X, Jorgensen ED, Gietl D, Traganos F, Darzynkiewicz Z. Induction of DNA double-strand breaks in A549 and normal human pulmonary epithelial cells by cigarette smoke is mediated by free radicals. Int J Oncol 2006;28:1491-1505.
96. Chauhan V, Howland M, Kutzner B, McNamee JP, Bellier PV, Wilkins RC. Biological effects of alpha particle radiation exposure on human monocytic cells. Int J Hyg Environ Health 2012;215:339-344.
97. Schults MA, Timmermans L, Godschalk RW, et al. Diminished carcinogen detoxification is a novel mechanism for hypoxiainducible factor 1-mediated genetic instability. J Biol Chem 2010;285:14558-14564.
98. Tang SC, Sheu GT, Wong RH, et al. Expression of glutathione S-transferase M2 in stage I/II non-small cell lung cancer and alleviation of DNA damage exposure to benzo[a]pyrene. Toxicol Lett 2010;192:316-323.
99. Zhao H, Traganos F, Darzynkiewicz Z. Kinetics of the UV-induced DNA damage response in relation to cell cycle phase. Correlation with DNA replication. Cytometry A 2010;77:285-293.
100. Hanasoge S, Ljungman M. H2AX phosphorylation afterUVirradiation is triggered byDNA repair intermediates and ismediated by the ATR kinase. Carcinogenesis 2007;28:2298-2304.
101. Usami N, Maeda M, Eguchi-Kasai K, Maezawa H, Kobayashi K. Radiation-induced gamma-H2AX inmammalian cells irradiated with a synchrotron X-ray microbeam. Radiat Prot Dosimetry 2006;122:307-309.
102. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced bymammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-20312.
103. Liu JS, Kuo SR,Melendy T. Comparison of checkpoint responses triggered by DNA polymerase inhibition versus DNA damaging agents. Mutat Res 2003;532:215-226.
104. Hamasaki K, Imai K, Nakachi K, Takahashi N, Kodama Y, Kusunoki Y. Short-term culture and gammaH2AX flow cytometry determine differences in individual radiosensitivity in human peripheral T lymphocytes. EnvironMolMutagen 2007;48:38-47.
105. Marchetti F, Coleman MA, Jones IM, Wyrobek AJ. Candidate protein biodosimeters of human exposure to ionizing radiation. Int J Radiat Biol 2006;82:605-639.
106. Olive PL, Bańath JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 2009;76:79-90.
107. Zhang T, Jiang T, Zhang F, Li C, Zhou YA, Zhu YF, Li XF. Involvement of p21Waf1/Cip1 cleavage during roscovitineinduced apoptosis in non-small cell lung cancer cells. Oncol Rep 2010;23:239-245.
108. Zhao H, Traganos F,Darzynkiewicz Z. Kinetics of histoneH2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Cytometry A 2008;73:480-489.
109. Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA, Marti TM. Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia 2011;13:961-970.
110. Kropotov AV, Grudinkin PS, Pleskach NM, Gavrilov BA, TomilinNV, Zhivotovsky B. Downregulation of peroxiredoxinV stimulates formation of etoposide-induced double-strand DNA breaks. FEBS Lett 2004;572:75-79.
111. Zhang F, Zhang T, Qu Y, et al. Replication-dependent ?-H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncology Reports 2010;24:1297-1305.
112. Zhang T, Cui GB, Zhang J, et al. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep 2010;24:1683-1689.
113. Deng J, Zhuang L, Chen Y. Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment. Zhongguo Fei Ai Za Zhi 2011;14:841-847.
114. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008;14:1266-1273.
115. Hubaux R, Vandermeers F, Crisanti MC, et al. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer 2010;46:1724-1734.
116. Jiang RH, SuWC, Liu HF, Huang HS, Chao JI. Opposite expression of securin and ?-H2AX regulates baicalein-induced cancer cell death. J Cell Biochem 2010;111:274-283.
117. Takahashi A,Matsumoto H, Nagayama K, et al. Evidence for the involvement of double-strand breaks in heat-induced cell killing. Cancer Res 2004;64:8839-8845.
118. Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY. Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther 2009;8:864-872.
119. Kamal A, Suresh P, Janaki Ramaiah M, et al. Synthesis and biological evaluation of 4?-acrylamidopodophyllotoxin congeners as DNA damaging agents. Bioorg Med Chem 2011;19:4589-4600.
120. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 2010;126:743-755.
121. Galluzzi L, Morselli E, Vitale I. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70:1793-1803.
122. Ghosh S, Narang H, Sarma A, Kaur H, Krishna M. Activation of DNA damage response signaling in lung adenocarcinoma A549 cells following oxygen beam irradiation. Mutat Res 2011;723:190-198.
123. Ghosh S,NarangH, Sarma A, KrishnaM. DNA damage response signaling in lung adenocarcinoma A549 cells following gamma and carbon beam irradiation. Mutat Res 2011;716:10-9.
124. Roig AI,Hight SK,Minna JD, Shay JW, Rusek A, StoryMD. DNA damage intensity in fibroblasts in a 3-dimensional collagen matrix correlates with the Bragg curve energy distribution of a high LET particle. Int J Radiat Biol 2010;86:194-204.
125. Kodym E, Kodym R, Choy H, Saha D. Sustained metaphase arrest in response to ionizing radiation in a non-small cell lung cancer cell line. Radiat Res 2008;169:46-58.
126. Sak A, Stueben G, Groneberg M, B̈ocker W, Stuschke M. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer 2005;92:1089-1097.
127. Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes nonsmall cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Therapy 2007;14:543-549.
128. Franken NA, ten Cate R, Krawczyk PM, Stap J, Haveman J, Aten J, Barendsen GW. Comparison of RBE values of high-LET ?-particles for the induction of DNA-DSBs, chromosome aberrations and cell reproductive death. Radiat Oncol 2011;8;6:64.
129. Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 2010;24:1307-1313.
130. Huang G,Wang H, Yang LX. Enhancement of radiation-induced DNAdamage and inhibition of its repair by a novel camptothecin analog. Anticancer Res 2010;30:937-944.
131. Patel K, Doudican NA, Schiff PB, Orlow SJ. Albendazole sensitizes cancer cells to ionizing radiation. Radiat Oncol 2011;17;6:160.
132. Xiong H, Lee RJ, Haura EB, Edwards JG, Dynan WS, Li S. Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit. Int J Radiat Oncol Biol Phys 2012;83:1023-1030.
133. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66:11298-11304.
134. Cuneo KC, Fu A, Osusky K, Huamani J, Hallahan DE, Geng L. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs 2007;18:793-800.
135. Zhang Y, AdachiM, Zou H, Hareyama M, Imai K, Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys 2006;65:859-866.
136. Lally BE, Geiger GA, Kridel S, et al. Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library. Cancer Res 2007;67:8791-8799.
137. Iwasa T, Okamoto I, Suzuki M, et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes nonsmall cell lung cancer cells. Clin Cancer Res 2009;15:5117-5125.
138. Singh-Gupta V, Joiner MC, et al. Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer. JThorac Oncol 2011;6:688-698.
139. Hudson D, Kovalchuk I, Koturbash I, Kolb B, Martin OA, Kovalchuk O. Induction and persistence of radiation-induced DNA damage is more pronounced in young animals than in old animals. Aging (Albany NY) 2011;3: 609-620.
140. Guo Q, Huang X, Zhang J, Luo Y, Peng Z, Li S. Downregulation of peroxiredoxin I by a novel fully human phage display recombinant antibody induces apoptosis and enhances radiation sensitization in A549 lung carcinoma cells. Cancer Biother Radiopharm 2012;27:307-316.
141. Iwasa T, Okamoto I, Suzuki M. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in nonsmall cell lung cancer cell lines. Clin Cancer Res 2008;14:6496-6504.
142. Sokolov MV, Dickey JS, Bonner WM, Sedelnikova OA. gamma-H2AX in bystander cells: not just a radiation-triggered event, a cellular response to stress mediated by intercellular communication. Cell Cycle 2007;6:2210-2212.
143. Klammer H, Kadhim M, Iliakis G. Evidence of an adaptive response targeting DNA nonhomologous end joining and its transmission to bystander cells. Cancer Res 2010;70:8498-8506.
144. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921.
145. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139-148.
146. Aguilar-Quesada R,Munoz-Ǵamez JA,Mart́?n-Oliva D, et al. Interaction betweenATMand PARP-1 in response toDNAdamage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol Biol 2007;25;8:29.
147. Albert JM, Cao C, Kim KW, et al. Inhibition of poly (ADPribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-3042.
148. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010;16:2344-2351.
149. Redon CE, Nakamura AJ, Zhang YW, et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010;16:4532-4542.
150. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
151. Kinders RJ, Hollingshead M, Khin S, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 2008;14:6877-6885.
152. Plummer R, Jones C,MiddletonM, et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-7923.
153. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64: 9152-9159.
154. Veuger SJ, Curtin NJ, Richardson CJ. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly (ADPribose) polymerase-1. Cancer Res 2003;63:6008-6015.
155. Kao J,MilanoMT, Javaheri A, GarofaloMC, Chmura SJ,Weichselbaum RR, Kron SJ. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets 2006;6:197-205.
156. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, Weichselbaum RR. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004;279:2273-2280.
157. Yu T,MacPhail SH, Bańath JP, Klokov D, Olive PL. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst) 2006;5:935-946.
158. Matthaios D, Foukas P, Kefala M, et al. ?-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Onco Targets Ther 2012;5:309-314.
159. Matthaios D, Bouros D, Kakolyris S. H2AX and lung cancer: Is it the Ariadne's thread? DNA Repair (Amst) 2013;12(2):90-91.
160. Euripides, Aeolus, fragment 38. Greek tragic dramatist (484 BC-406 BC)